Short-Term Outcomes of Intravitreal Faricimab Injection for Diabetic Macular Edema

1.

2.

3.

4.

5.

6.

7.

8.

9.

10.

11.

12.

13.

14.

15.

Kusuhara, S.; Fukushima, Y.; Ogura, S.; Inoue, N.; Uemura, A. Pathophysiology of diabetic retinopathy: The old and the new.

Diabetes Metab. J. 2018, 42, 364–376. [CrossRef] [PubMed]

Nguyen, Q.D.; Brown, D.M.; Marcus, D.M.; Boyer, D.S.; Patel, S.; Feiner, L.; Gibson, A.; Sy, J.; Rundle, A.C.; Hopkins, J.J.; et al.

Ranibizumab for diabetic macular edema: Results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 2012, 119,

789–801. [CrossRef] [PubMed]

Korobelnik, J.F.; Do, D.V.; Schmidt-Erfurth, U.; Boyer, D.S.; Holz, F.G.; Heier, J.S.; Midena, E.; Kaiser, P.K.; Terasaki, H.; Marcus,

D.M.; et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology 2014, 121, 2247–2254. [CrossRef] [PubMed]

Bressler, S.B.; Ayala, A.R.; Bressler, N.M.; Melia, M.; Qin, H.; Ferris, F.L., 3rd; Flaxel, C.J.; Friedman, S.M.; Glassman, A.R.; Jampol,

L.M.; et al. Persistent macular thickening after ranibizumab treatment for diabetic macular edema with vision impairment. JAMA

Ophthalmol. 2016, 134, 278–285. [CrossRef] [PubMed]

Sahni, J.; Patel, S.S.; Dugel, P.U.; Khanani, A.M.; Jhaveri, C.D.; Wykoff, C.C.; Hershberger, V.S.; Pauly-Evers, M.; Sadikhov, S.;

Szczesny, P.; et al. Simultaneous Inhibition of angiopoietin-2 and vascular endothelial growth factor-a with faricimab in diabetic

macular edema: BOULEVARD phase 2 randomized trial. Ophthalmology 2019, 126, 1155–1170. [CrossRef] [PubMed]

Brown, D.M.; Boyer, D.S.; Csaky, K.; Vitti, R.; Perlee, L.; Chu, K.W.; Asmus, F.; Leal, S.; Zeitz, O.; Cheng, Y.; et al. Intravitreal

nesvacumab (antiangiopoietin 2) plus aflibercept in diabetic macular edema: Phase 2 RUBY randomized trial. Retina 2022, 42,

1111–1120. [CrossRef] [PubMed]

Wykoff, C.C.; Abreu, F.; Adamis, A.P.; Basu, K.; Eichenbaum, D.A.; Haskova, Z.; Lin, H.; Loewenstein, A.; Mohan, S.; Pearce,

I.A.; et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with

diabetic macular oedema (YOSEMITE and RHINE): Two randomised, double-masked, phase 3 trials. Lancet 2022, 399, 741–755.

[CrossRef] [PubMed]

Talks, J.; Daien, V.; Finger, R.P.; Eldem, B.; Sakamoto, T.; Cardillo, J.A.; Mitchell, P.; Wong, T.Y.; Korobelnik, J.F. The use of realworld evidence for evaluating anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration.

Surv. Ophthalmol. 2019, 64, 707–719. [CrossRef] [PubMed]

Glassman, A.R.; Wells, J.A., 3rd; Josic, K.; Maguire, M.G.; Antoszyk, A.N.; Baker, C.; Beaulieu, W.T.; Elman, M.J.; Jampol, L.M.;

Sun, J.K. Five-year outcomes after initial aflibercept, bevacizumab, or ranibizumab treatment for diabetic macular edema (Protocol

T Extension Study). Ophthalmology 2020, 127, 1201–1210. [CrossRef] [PubMed]

Rush, R.B.; Rush, S.W. Faricimab for treatment-resistant diabetic macular edema. Clin. Ophthalmol. 2022, 16, 2797–2801. [CrossRef]

[PubMed]

Sorour, O.A.; Levine, E.S.; Baumal, C.R.; Elnahry, A.G.; Braun, P.; Girgis, J.; Waheed, N.K. Persistent diabetic macular edema:

Definition, incidence, biomarkers, and treatment methods. Surv. Ophthalmol. 2023, 68, 147–174. [CrossRef] [PubMed]

Brown, D.M.; Emanuelli, A.; Bandello, F.; Barranco, J.J.E.; Figueira, J.; Souied, E.; Wolf, S.; Gupta, V.; Ngah, N.F.; Liew, G.; et al.

KESTREL and KITE: 52-Week Results From Two Phase III Pivotal Trials of Brolucizumab for Diabetic Macular Edema. Am. J.

Ophthalmol. 2022, 238, 157–172. [CrossRef] [PubMed]

Baumal, C.R.; Sorensen, T.L.; Karcher, H.; Freitas, R.L.; Becher, A.; Balez, S.; Clemens, A.; Singer, M.; Kodjikian, L. Efficacy and

safety of brolucizumab in age-related macular degeneration: A systematic review of real-world studies. Acta Ophthalmol. 2023,

101, 123–139. [CrossRef] [PubMed]

Joussen, A.M.; Ricci, F.; Paris, L.P.; Korn, C.; Quezada-Ruiz, C.; Zarbin, M. Angiopoietin/Tie2 signalling and its role in retinal and

choroidal vascular diseases: A review of preclinical data. Eye 2021, 35, 1305–1316. [CrossRef] [PubMed]

Khanani, A.M.; Russell, M.W.; Aziz, A.A.; Danzig, C.J.; Weng, C.Y.; Eichenbaum, D.A.; Singh, R.P. Angiopoietins as potential

targets in management of retinal disease. Clin. Ophthalmol. 2021, 15, 3747–3755. [CrossRef] [PubMed]

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual

author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to

people or property resulting from any ideas, methods, instructions or products referred to in the content.

...